Report – ‘Progress Made' In Inter & AC Milan Meeting With City On San Siro But Nothing Decisive Yet
Inter Milan and AC Milan have reportedly made 'progress' in recent talks with the city of Milan about the new San Siro project.
This according to today's print edition of Rome-based newspaper La Repubblica, via FCInterNews.
Advertisement
Inter Milan and AC Milan continue to work on their efforts to build a new stadium in the San Siro area.
The two clubs will not be able to tear down the existing stadium and build in its place. However, they are planning to build a new stadium in the San Siro, adjacent to the current one.
Inter & AC Milan 'Make Progress' In Talks With City On San Siro
MILAN, ITALY – APRIL 23: General view outside the stadium prior to the coppa Italia Semi Final match between FC Internazionale and AC Milan at Stadio Giuseppe Meazza on April 23, 2025 in Milan, Italy. (Photo by)
According to La Repubblica, there was a meeting between Inter, AC Milan, and the city of Milan yesterday.
Representing the Rossoneri were club President Paolo Scaroni and senior figures from owners RedBird Capital.
Meanwhile, senior figures from owners of Inter Oaktree Capital were also at the meeting.
Advertisement
According to La Repubblica, this meeting was not the decisive one.
However, the clubs and the city made progress. They discussed issues of land reclamation and demolition in the project.
Meanwhile, La Repubblica report, the clubs and the city are both determined to finalize the sale of the land within the established timeframe. Moreover, it shouldn't be too tough to agree a sale price of the land.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Car import quotas, export credits on table for EU-US trade talks, sources say
By Christoph Steitz, Julia Payne and David Lawder FRANKFURT/BRUSSELS/WASHINGTON (Reuters) -Brussels is discussing with U.S. counterparts a range of measures aimed at protecting the European Union's auto industry from steep U.S. import duties, including tariff cuts, import quotas and credits against the value of EU automakers' U.S. exports, industry sources and trade officials say. The talks are part of efforts by the European Commission, the bloc's executive branch, to reach a trade agreement outline with the United States in the coming days, ahead of the August 1 deadline set by U.S. President Donald Trump for broad tariff increases. Trump said on Tuesday he would "probably" tell the EU within two days what rate it could expect for its exports to the U.S., adding that the 27-nation bloc had become much more cooperative. EU negotiators have sought relief from tariffs in key sectors such as autos and aerospace. One EU diplomat previously said cars were a "red line" for the bloc, making a U.S. concession on cars a caveat of any deal. Since April, EU carmakers have incurred a 25% U.S. import tariff on top of the 2.5% already in place. The levy is separate from Trump's prior threatened 20% "reciprocal" tariff announced in April but dialed back to 10%. Discussions are ongoing and it is unclear if the U.S. administration will agree to all terms from its biggest bilateral trading partner, the sources said. The White House, the U.S. Trade Representative's Office and the Commerce Department did not immediately respond to requests for comment on the U.S.-EU negotiations. The European Commission also had no immediate comment for this story. EU trade chief Maros Sefcovic said on Wednesday the Commission has made good progress on a framework trade agreement with the United States and a deal may be possible in the coming days. The sources - two European industry sources, three European officials and three U.S. industry sources familiar with the talks - declined to be identified because the talks are confidential. EXPORT CREDITS A U.S. source and one European official said things are moving "fast" in the negotiations. On the table is a proposal that would provide some relief from import tariffs for carmakers that produce vehicles in the United States and export them to other countries, three of the sources said. Under that plan, carmakers that export vehicles from the U.S. would get credits for that export value, which could then be applied against the value of any imports from the EU into the U.S., the U.S. source said. That would allow companies to import that value of vehicle duty-free or at a reduced rate, while anything above it would be subject to the maximum tariff. Such a mechanism would benefit carmakers BMW and Mercedes-Benz, which both have major production hubs in the United States for sport-utility vehicles, with a significant share of their output exported. Two sources said the U.S. had offered some relief if a company agrees to make additional investment, a mechanism that would help Volkswagen, which barely exports out of U.S. plants but is weighing a local factory for its Audi brand. The terms are a delicate balancing act for Brussels as it tries to find concessions that are acceptable to carmakers such as BMW, Porsche, Volkswagen and Mercedes-Benz, as well as to the Trump administration, which wants to boost U.S. manufacturing and create jobs. TARIFF RATES, QUOTAS DISCUSSED Europe shipped nearly 758,000 cars worth 38.9 billion euros ($45.57 billion) to the U.S. in 2024, more than four times as many as in the other direction, according to data from European auto association ACEA. Two of the sources said the framework may be similar to the one agreed with Britain in May. In that deal, the U.S. cut tariffs on British-made cars to 10% and British carmakers received a import quota of 100,000 cars a year at the lower tariff rate, almost the total Britain exported last year. While the EU had proposed a similar tariff-rate quota with a certain number of vehicles imported, two U.S. industry sources said the Trump administration was leaning against this. Three sources said both sides have discussed cutting their respective auto import tariffs from current levels - 27.5% for imports into the U.S., and 10% for imports into the EU. Non-tariff elements such as standardising regulation, for example in the area of auto safety tests, are also being offered by the EU, one of the people said. ($1 = 0.8536 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Fiorentina star on Man Utd radar after 19-goal breakthrough season
Moise Kean, Manchester United and the Long Road from Misjudged Talent to Maturing Striker Kean's evolution in Florence reopens Premier League doors Football often holds an unforgiving memory. For Moise Kean, the image etched into the collective Premier League consciousness remains that winter afternoon at Old Trafford in 2019. Brought on by Duncan Ferguson as a second-half substitute, then swiftly taken off within 18 minutes. It was a damning symbol, a visual shorthand for potential misread and squandered. Photo IMAGO Advertisement Now, five years later, Manchester United are among the clubs monitoring the Fiorentina forward's progress. As reported in The Athletic, Kean has a €52 million release clause active until July 15. It marks an unlikely, even ironic return to the narrative, Old Trafford potentially becoming the stage for his resurgence. And the resurgence is no mirage. Kean's 2024-25 campaign under Raffaele Palladino in Serie A was not just productive, it was transformative. Structure and trust deliver Kean's best form Much of Kean's early club career was spent bouncing between systems, roles and leagues. Juventus gave him little rhythm. Everton even less. A short loan at PSG flashed promise, but consistency evaded him. Advertisement Florence changed that. Palladino placed trust in him as the focal point of Fiorentina's attack and allowed Kean to operate where he is most effective, centrally, on the shoulder of the last defender, rather than drifting wide or reacting to tactical emergency. Photo: IMAGO Palladino was emphatic. 'Both I and the club have faith in Moise, and that might seem banal, but it is fundamental for a player.' The clarity of that belief translated into 19 Serie A goals, second only to Mateo Retegui of Atalanta. Only one of those strikes came from outside the box, and even that was a gift, a backpass snaffled before a calm finish past Yann Sommer. But that, in a way, said everything about Kean's game now. Direct, instinctive, rarely wasteful. Advertisement His presence in the penalty area has grown. Six shots on target per 100 touches last season was the highest rate in Serie A. It placed him well ahead of Rasmus Hojlund (2.2) and Joshua Zirkzee (2.45), two forwards United have heavily invested in or considered. Photo IMAGO Where Hojlund struggled to convert limited service and Zirkzee offered fleeting moments of guile, Kean gave Fiorentina relentless movement. Tracking data showed 39 per cent of his runs were made in behind defensive lines. It's the hallmark of a forward thinking a fraction quicker than his marker. Style of play and tactical identity Kean's hat-trick against Verona encapsulated his evolution. A clever diagonal run for his first, a strong aerial finish for his second, then a slaloming solo effort from the left channel for his third. Advertisement He is now a forward who asks questions of defenders, rather than reacting to what's given. The variety in his finishes illustrates a striker no longer trying to do too much, but simply doing what matters. Photo IMAGO What might be more significant for Manchester United is what this reveals about Fiorentina's role in that improvement. It is not simply that Kean became more prolific, but that the team around him understood how to extract his strengths. Regular minutes, repetition, an understanding of his movement patterns. This is where coaching and recruitment philosophies either collide or coalesce. Advertisement For United's head coach Ruben Amorim, that poses an interesting question. Does Kean offer the kind of pressing, linking and multi-phase involvement his system demands? Or does the Italian provide something more direct, a kind of explosive Plan B when combinations fail? There is no clear answer. What is evident is that Kean is not the player many remember. He is not the brooding teenager trudging off at Old Trafford, nor the Everton enigma shadowed by systemic dysfunction. He is 25, a player with identity and purpose, who knows where to be in the box and how to finish. Photo IMAGO English memory and the risk of misjudgement Kean's Premier League past has unfairly clouded his potential. English football often preserves reductive versions of players. Iago Aspas is remembered for one misplaced corner, not for nine seasons of prolific returns at Celta Vigo. Advertisement That sort of memory trap risks repeating itself. Kean was a teenager in 2019. His substitution by Ferguson, as ignominious as it appeared, said more about managerial instinct than footballing ability. The broader narrative ignored context, growth and age. Now, he is emerging from the shadows, but in a different light. There is nuance to his game, and strength in his simplicity. He plays within his limits, not constrained by them. For United, there is intrigue. Not just in whether Kean fits their tactical needs, but in whether their cultural instincts can move past a single snapshot of perceived failure. Our View – EPL Index Analysis United fans will remember Moise Kean for those 18 miserable minutes. That moment at Old Trafford became one of those viral clips passed around every time a debate sparked about young talent not cutting it in England. So the idea of him returning, not just to the Premier League but potentially to United, feels oddly dissonant. Advertisement There's also the scepticism that comes with good numbers abroad. Nineteen goals in Serie A, yes, but is Serie A's pace and quality comparable? Will he adapt to the pressing intensity? Will he track back like Amorim wants his forwards to? Or is this another Memphis Depay scenario waiting to happen, all promise, minimal delivery? Even the reported fee gives cause for pause. £45 million is a considerable amount for a striker who has not yet delivered in English football. United have had their fingers burned enough times to hesitate. Wout Weghorst, Odion Ighalo, even Hojlund for now, all brought in to fill a No 9 void and all still leaving fans craving more. If Kean signs, he will need to hit the ground sprinting, not just running. Old memories will not fade easily. But if he can match the Serie A sharpness with Premier League application, he might just surprise supporters.
Yahoo
17 minutes ago
- Yahoo
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality Assurance These key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ('Inventiva' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH'), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development ('R&D') and Chief Medical Officer ('CMO') and Martine Zimmermann, PharmD, as Executive Vice President ('EVP') of Regulatory Affairs and Quality Assurance. Dr. Campagna is joining Inventiva's executive leadership team and brings extensive expertise in the MASH field. He succeeds Pierre Broqua, PhD, co-founder and Chief Scientific Officer, who is transitioning to a consulting role as Scientific Advisor, and Michael Cooreman, MD, departing as CMO of the Company. Dr. Campagna most recently was the CMO at Q32 Bio and prior to that was the MASH Global Program Lead and CMO at Intercept Pharmaceuticals. Dr. Zimmermann is also joining the Company's executive leadership team. She was most recently Senior Vice President, Head of Regulatory Affairs at Ipsen where she successfully led a team that secured regulatory approvals of two liver disease drugs, including Iqirvo®, a dual PPARα/δ agonist, for the treatment of primary biliary cholangitis. Prior to Ipsen, Dr. Zimmermann was Senior Vice President and Head of Global Regulatory Affairs & Quality at Alexion Pharma (also known as AstraZeneca Rare Disease). Frederic Cren, CEO of Inventiva stated: 'Jason and Martine both bring exceptional leadership and experience during this pivotal time for the Company as we plan for the readout of our NATiV3 Phase 3 study next year and lanifibranor's potential regulatory approval and commercialization. Having played an integral part in the creation and building of Inventiva, Pierre will continue to actively support the team in a scientific consulting role. I would also like to express my gratitude to Michael for his scientific leadership and contributions in advancing lanifibranor to this stage and we wish him every success in his future endeavors.' Jason Campagna, MD, PhD, President, R&D and CMO of Inventiva commented: 'Inventiva has built a robust scientific and clinical foundation, and I'm thrilled to join the team at this pivotal moment as we advance lanifibranor toward anticipated regulatory submissions. Having led the design and execution of one of the field's most advanced clinical programs at Intercept—including the first-ever NDA submission in this indication—I've seen firsthand both the scientific complexity and the urgency of bringing effective therapies to patients with MASH. I believe the promising results of the Phase 2b NATIVE trial reflect the thoughtful design of lanifibranor development program—and that's deeply exciting to me. With lanifibranor well on its way in the Phase 3 NATiV3 registrational trial, I look forward to working closely with the exceptional team at Inventiva to deliver on the promise of bringing a novel treatment to patients with MASH.' Martine Zimmermann, PharmD, Executive Vice President of Regulatory Affairs and Quality Assurance of Inventiva said: "I'm excited to take on this leadership role at a time when Inventiva is entering a critical regulatory phase for lanifibranor, a first-in-class pan-PPAR agonist for the treatment of MASH. In my career, I've been closely involved in leading global regulatory strategy and approval of compounds for the treatment of chronic liver diseases, including a PPAR, in a number of geographies, including the US, Europe and Japan. I am now eager to apply that experience to support lanifibranor toward a potential approval." About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts InventivaPascaline ClercEVP, Strategy and Corporate Affairsmedia@ 202 499 8937 ICR HealthcareMedia relations Alexis Feinberg inventivapr@ +1 203 939 2225 ICR HealthcarePatricia L. BankInvestor relations +1 415 513 1284 Important Notice This press release contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's clinical trials, including Inventiva's ongoing NATiV3 Phase 3 clinical trial of lanifibranor in MASH, including related timing and regulatory matters with respect thereto, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva's product candidates, potential regulatory submissions, approvals and commercialization, the effective start date of Dr. Campagna and Mrs. Zimmerman, the clinical development of and regulatory plans and pathway for lanifibranor, and future activities, expectations, plans, growth and prospects of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'would', 'could', 'might', 'should', 'designed', 'hopefully', 'target', 'potential', 'possible', 'aim', and 'continue' and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing, to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to identify additional products or product candidates with significant commercial potential, Inventiva's expectations with respect to its pipeline prioritization plan and related workforce reduction, including whether the plan will be implemented and the timing, potential benefits, expenses and consequences relating thereto, Inventiva's ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and pre-clinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in law and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, political turmoil and natural catastrophes, uncertain financial markets and disruptions in banking systems. The review of potential financial and strategic options may not result in any particular action or transaction being pursued, entered into or consummated, and there is no assurance as to the timing, sequence or outcome of any action or transaction or series of actions or transactions. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2024, filed with the Autorité des Marchés Financiers on April 15, 2025, and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the 'SEC') on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption 'Risk Factors' and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. Attachment Inventiva - PR - Leadership Team Changes- EN - 07 09 2025Sign in to access your portfolio
